FindTrial
Sign In

The value of Serum Human Epididymis Secretory Protein 4(HE4) alteration in dynamic mornitoring and prognosis predicition of epithelial ovarian cancer

The value of Serum Human Epididymis Secretory Protein 4(HE4) alteration in dynamic mornitoring and prognosis predicition of epithelial ovarian cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-11001516
Enrollment
Unknown
Registered
2011-01-06
Start date
2005-11-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Cancer

Interventions

Gold Standard:
Index test:

Sponsors

Peking University People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: epithelial ovarian cancer or primary carcinoma of fallopian tube or primary peritoneal cancer diagnosed and treated in Peking University People's Hospital,and have no less than 2 blood sample in differen't stage

Exclusion criteria

Exclusion criteria: 1. non-epithelial ovarian cancer; 2. haemolysis of blood sample; 3. unavailable for follow up.

Design outcomes

Primary

MeasureTime frame
the concentration of Serum Human Epididymis Secretory Protein 4 (HE4);—

Secondary

MeasureTime frame
median progress-free survival (PFS);—

Countries

China

Contacts

Public ContactCuiHeng
cuiheng20@163.com+86 010 88324472

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026